Cost–Effectiveness of Nanomedicine: Estimating the Real Size of Nano-Costs

Abstract

The nanomedicine market: small particles; tremendous potential Nanoparticles have already demonstrated their clinical potential, showing their ability to change the course of diagnostics and therapy [1,2].The number of products with enhanced therapeutic efficacy due to their nanoscale dimensions is skyrocketing.The availability of nano-based therapeutics on the rapidly emerging nanomedicine market is growing, while an even greater number of nanodrugs are undergoing clinical investigation [3][4][5].The big business of nanomedicines had an estimated value of US$53 billion in 2009 [6].The industry is projected to reach a total market value of approximately US$334 billion by 2025 [7,8].Soon, the first-generation nanodrugs will start going off-patent, while an increasing number of new generation nanotherapeutics (around 40% of nanodrugs are currently in Phase II clinical trials) will enter the market, creating more market value [7,9].According to the Grand View Research Report, the USA remains the leader in the nanomedicine industry, owning 46% of the total international nanomedicine revenue in 2016 [9], followed by Europe [10].Japan is considered an emerging but attractive nanomedicine player [10].Major industry players in the market include Pfizer Inc. (NY, USA)

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 117 citations exist upstream.